NYSE : BAX

Baxter International Inc.

$22.15 USD

$0.35 (1.61%)

Volume
3.78M
Average Volume
7.16M
Market Capitalization
$11.44B
P/E Ratio
-10.55
Dividend Yield
0.90%
Price Target
$20.00
Year High
$29.35
Year Low
$15.73
Day High
Day Low
Payout Ratio
-$0.24
Current Ratio
$1.85
Source Headline
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day.

247wallst.com - 2026-07-15 07:45:54

Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/167756971 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.bax.

businesswire.com - 2026-07-09 16:10:00

Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact

Baxter International Inc. (NYSE: BAX), a global medtech leader, today published its newly renamed [url="]2025 Sustainability Report[/url], highlighting the comp

gurufocus.com - 2026-06-22 10:00:00

Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company's progress and refreshed approach to advancing a sustainable and responsible business model. “As we shape Baxter's next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while working to create long‑term value for all stakeholders,” said Andrew Hider, presiden.

businesswire.com - 2026-06-22 09:00:00

Baxter's Unit Synovis MCA to Lead Global Rollout of the SHIYA Platform

BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.

zacks.com - 2026-06-19 11:25:38

Reasons to Retain Baxter International Stock in Your Portfolio for Now

BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.

zacks.com - 2026-06-16 15:16:09

Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 14:42:10

Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-13 16:40:44

Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting

Baxter International NYSE: BAX held its 2026 annual meeting of stockholders by webcast, with shareholders giving preliminary approval to all five proposals presented by the company, including the election of nine directors, executive compensation, auditor ratification, an amended incentive plan and a change related to board size.

marketbeat.com - 2026-05-09 21:06:27

Baxter International Still Has A Path To Upside

In recent years, stocks like Baxter International have underperformed: most low-growth, high-debt, struggling names have been bad investments at basically any price. Concerns are real, and early missteps under new CEO Andrew Hider haven't helped. But valuation is attractive not just on an absolute basis but also relative to the outlook, and Q1 results seemed helpful to the bull case.

seekingalpha.com - 2026-05-07 22:30:39

Madison Small Cap Fund Q1 2026 Portfolio Activity

ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period because the company's success drove its market cap to $12B.

seekingalpha.com - 2026-05-04 22:35:00

Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript

Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-30 15:51:36

BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract

Baxter beats Q1 earnings and revenue estimates, sending shares higher despite declining profits and margin contraction.

zacks.com - 2026-04-30 11:45:39

Baxter (BAX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-04-30 11:30:15

Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates

Baxter International (BAX) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago.

zacks.com - 2026-04-30 09:30:20

Baxter beats quarterly expectations on strong demand for medical devices

Baxter on Thursday beat Wall Street estimates for first-quarter profit and revenue, helped by robust sales ​in its medical products and therapies unit.

reuters.com - 2026-04-30 08:26:37

Is Baxter International (BAX) 53.0% Undervalued After Q1 2026 Earnings Beat? Adjusted EPS $0.36 vs $0.11 est; Revenue $2.70B vs $2.62B est -- GF Score 57/100

On April 30, 2026, Baxter International Inc (BAX) released its 8-K filing detailing first-quarter 2026 results. Sales from continuing operations were $2.7 billi

gurufocus.com - 2026-04-30 07:41:00

Baxter Reports First-Quarter 2026 Results

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global medtech leader, today reported results for the first quarter of 2026. “Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution,” said Andrew Hider, president and CEO. “Although more work remains to achieve our full potential, Baxter continues to take the decisive steps nec.

businesswire.com - 2026-04-30 07:15:00

Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline

QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-28 11:06:47

Baxter Q1 Preview: Will Operational Headwinds Weigh on Results Again?

BAX heads into Q1 earnings with revenues and profit set to fall sharply as operational pressures, weak demand and product disruptions weigh on results.

zacks.com - 2026-04-27 13:36:11

Baxter International (NYSE:BAX) vs. GN Store Nord (OTCMKTS:GNNDY) Head-To-Head Analysis

Baxter International (NYSE: BAX - Get Free Report) and GN Store Nord (OTCMKTS:GNNDY - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Risk and Volatility Baxter International has

defenseworld.net - 2026-04-27 01:12:47

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-23 11:03:27

Get BAX Insider Trade Alerts

BAX Price Target Summary

Last Month

$22.50

2 analysts

Last Quarter

$24.00

3 analysts

Last Year

$22.76

17 analysts

All Time

$47.00

37 analysts

BAX Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-15 Goldman Sachs Maintain Neutral Neutral
2026-07-06 Evercore ISI Group Maintain Outperform Outperform
2026-05-28 Citigroup Downgrade Neutral Sell
2026-05-04 Barclays Maintain Overweight Overweight
2026-04-06 Evercore ISI Group Maintain Outperform Outperform
2026-03-11 Citigroup Maintain Neutral Neutral
2026-02-17 Goldman Sachs Maintain Neutral Neutral
2026-02-13 Barclays Maintain Overweight Overweight
2026-01-09 Barclays Maintain Overweight Overweight
2025-12-02 Morgan Stanley Maintain Underweight Underweight
2025-10-31 Citigroup Maintain Neutral Neutral
2025-10-31 Argus Research Downgrade Buy Hold
2025-10-31 Goldman Sachs Maintain Neutral Neutral
2025-10-31 UBS Maintain Neutral Neutral
2025-10-07 Evercore ISI Group Maintain Outperform Outperform
2025-08-04 Stifel Downgrade Buy Hold
2025-08-04 UBS Maintain Neutral Neutral
2025-08-04 Barclays Maintain Overweight Overweight
2025-08-01 Wells Fargo Maintain Equal Weight Equal Weight
2025-07-15 Morgan Stanley Maintain Underweight Underweight
2025-07-09 Citigroup Maintain Neutral Neutral
2025-07-08 Evercore ISI Group Maintain Outperform Outperform
2025-05-05 Morgan Stanley Maintain Underweight Underweight
2025-05-02 Wells Fargo Maintain Equal Weight Equal Weight
2025-03-10 Barclays Maintain Overweight Overweight
2025-02-21 JP Morgan Maintain Neutral Neutral
2024-12-11 Citigroup Maintain Neutral Neutral
2024-11-11 Stifel Maintain Buy Buy
2024-10-01 Citigroup Maintain Neutral Neutral
2024-08-08 Goldman Sachs Maintain Neutral Neutral
2024-08-07 JP Morgan Maintain Neutral Neutral
2024-08-07 Wells Fargo Maintain Equal Weight Equal Weight
2024-07-15 Morgan Stanley Downgrade Equal Weight Underweight
2024-07-10 Citigroup Maintain Neutral Neutral
2024-07-02 Evercore ISI Group Maintain Outperform Outperform
2024-05-22 Citigroup Maintain Neutral Neutral
2024-05-10 TD Cowen Downgrade Buy Hold
2024-04-03 Citigroup Maintain Neutral Neutral
2024-03-05 B of A Securities Maintain Neutral Neutral
2024-02-12 Barclays Maintain Overweight Overweight
2024-02-09 JP Morgan Maintain Neutral Neutral
2023-12-04 Morgan Stanley Maintain Equal Weight Equal Weight
2023-10-31 JP Morgan Maintain Neutral Neutral
2023-08-21 Citigroup Maintain Neutral Neutral
2023-08-01 Barclays Maintain Overweight Overweight
2023-07-31 Keybanc Maintain Overweight Overweight
2023-07-31 Barclays Maintain Overweight Overweight
2023-07-28 Wells Fargo Maintain Equal Weight Equal Weight
2023-07-12 Stifel Maintain Buy Buy
2023-05-01 Barclays Maintain Overweight Overweight
2023-04-28 Citigroup Maintain Neutral Neutral
2023-04-28 Deutsche Bank Maintain Hold Hold
2023-04-28 Keybanc Maintain Overweight Overweight
2023-04-28 Stifel Maintain Buy Buy
2023-04-28 Morgan Stanley Maintain Equal Weight Equal Weight
2023-04-04 Evercore ISI Group Maintain Outperform Outperform
2023-03-29 UBS Maintain Neutral Neutral
2023-02-13 Barclays Maintain Overweight Overweight
2023-02-13 Citigroup Maintain Neutral Neutral
2023-02-10 Wells Fargo Maintain Equal Weight Equal Weight
2023-02-10 Keybanc Maintain Overweight Overweight
2023-02-10 Morgan Stanley Maintain Equal Weight Equal Weight
2023-02-10 Cowen & Co. Maintain Outperform Outperform
2023-02-06 Keybanc Maintain Overweight Overweight
2023-01-09 Wells Fargo Maintain Equal Weight Equal Weight
2023-01-06 Morgan Stanley Downgrade Overweight Equal Weight
2023-01-05 Raymond James Downgrade Outperform Market Perform
2023-01-03 B of A Securities Downgrade Buy Neutral
2022-12-19 JP Morgan Downgrade Overweight Neutral
2022-12-15 Wells Fargo Maintain Equal Weight Equal Weight
2022-12-15 Deutsche Bank Downgrade Buy Hold
2022-12-12 Citigroup Downgrade Buy Neutral
2022-11-03 Goldman Sachs Maintain Sell Sell
2022-10-28 Raymond James Maintain Outperform Outperform
2022-10-28 Wells Fargo Maintain Equal Weight Equal Weight
2022-10-28 Keybanc Maintain Overweight Overweight
2022-10-18 Barclays Maintain Overweight Overweight
2022-10-12 Jefferies Maintain Hold Hold
2022-10-11 Morgan Stanley Maintain Overweight Overweight
2022-08-03 Goldman Sachs Maintain Sell Sell
2022-07-29 Raymond James Maintain Outperform Outperform
2022-07-29 Morgan Stanley Maintain Overweight Overweight
2022-07-19 Morgan Stanley Maintain Overweight Overweight
2022-07-18 Stifel Maintain Buy Buy
2022-07-15 Morgan Stanley Maintain Overweight Overweight
2022-06-24 JP Morgan Maintain Overweight Overweight
2022-06-24 Wells Fargo Downgrade Overweight Equal Weight
2022-05-23 Morgan Stanley Maintain Overweight Overweight
2022-05-17 Citigroup Maintain Buy Buy
2022-04-29 Morgan Stanley Maintain Overweight Overweight
2022-04-29 Wells Fargo Maintain Overweight Overweight
2022-04-29 Keybanc Maintain Overweight Overweight
2022-04-29 Raymond James Maintain Outperform Outperform
2022-04-04 Goldman Sachs Downgrade Neutral Sell
2022-02-18 Raymond James Maintain Outperform Outperform
2022-02-18 Morgan Stanley Maintain Overweight Overweight
2022-02-18 Keybanc Maintain Overweight Overweight
2022-01-07 Morgan Stanley Upgrade Equal Weight Overweight
2022-01-04 Raymond James Maintain Outperform Outperform
2022-01-04 Keybanc Maintain Overweight Overweight
2021-10-29 Morgan Stanley Maintain Equal Weight Equal Weight
2021-09-13 Cowen & Co. Upgrade Market Perform Outperform
2021-09-03 Barclays Upgrade Equal Weight Overweight
2021-08-03 Goldman Sachs Maintain Neutral Neutral
2021-08-02 Keybanc Maintain Overweight Overweight
2021-05-25 Barclays Maintain Equal Weight Equal Weight
2021-04-30 Citigroup Maintain Buy Buy
2021-02-05 Credit Suisse Maintain Outperform Outperform
2021-02-05 Raymond James Maintain Outperform Outperform
2021-01-29 Piper Sandler Downgrade Overweight Neutral
2020-12-15 Morgan Stanley Maintain Equal Weight Equal Weight
2020-11-02 Stifel Maintain Buy Buy
2020-10-30 KeyBanc Maintain Overweight Overweight
2020-10-30 Morgan Stanley Maintain Equal Weight Equal Weight
2020-10-30 Keybanc Maintain Overweight Overweight
2020-10-12 Raymond James Maintain Outperform Outperform
2020-10-09 UBS Maintain Buy Buy
2020-10-01 Citigroup Upgrade Neutral Buy
2020-09-04 Argus Research Downgrade Buy Hold
2020-07-31 Raymond James Maintain Outperform Outperform
2020-07-31 Morgan Stanley Maintain Equal Weight Equal Weight
2020-06-24 Oppenheimer Maintain Outperform Outperform
2020-05-01 Keybanc Maintain Overweight Overweight
2020-05-01 UBS Maintain Buy Buy
2020-05-01 Credit Suisse Maintain Outperform Outperform
2020-05-01 KeyBanc Maintain Overweight Overweight
2020-05-01 SVB Leerink Maintain Outperform Outperform
2020-04-28 JP Morgan Maintain Overweight Overweight
2020-04-13 Raymond James Maintain Outperform Outperform
2020-03-27 Morgan Stanley Maintain Equal Weight Equal Weight
2020-03-19 Stifel Upgrade Hold Buy
2020-03-18 Raymond James Maintain Outperform Outperform
2020-03-18 Deutsche Bank Maintain Buy Buy
2020-03-18 KeyBanc Upgrade Sector Weight Overweight
2020-03-18 Keybanc Upgrade Sector Weight Overweight
2020-03-18 Citigroup Maintain Neutral Neutral
2020-03-18 Credit Suisse Maintain Outperform Outperform
2020-03-06 Credit Suisse Maintain Outperform Outperform
2020-03-05 Citigroup Maintain Neutral Neutral
2020-02-14 Wells Fargo Maintain Overweight Overweight
2020-02-13 Goldman Sachs Maintain Buy Buy
2020-02-06 CFRA Maintain Hold Hold
2020-01-16 Wells Fargo Maintain Overweight Overweight
2020-01-02 Evercore ISI Group Upgrade In Line Outperform
2019-12-20 JP Morgan Maintain Overweight Overweight
2019-12-17 Morgan Stanley Downgrade Overweight Equal Weight
2019-10-28 UBS Maintain Buy Buy
2019-07-26 Credit Suisse Maintain Outperform Outperform
2019-06-26 Wells Fargo Maintain Outperform Outperform
2019-06-26 KeyBanc Maintain Sector Weight Equal Weight
2019-04-15 Barclays Maintain Equal Weight Equal Weight
2019-04-08 Evercore ISI Group Downgrade Outperform In Line
2019-04-03 Wells Fargo Maintain Outperform Outperform
2019-03-05 Morgan Stanley Maintain Overweight Overweight
2019-02-01 Barclays Upgrade Underweight Equal Weight
2019-01-02 Citigroup Upgrade Neutral Buy
2019-01-02 Morgan Stanley Upgrade Equal Weight Overweight
2018-12-18 Credit Suisse Maintain Outperform Outperform
2018-12-04 Wells Fargo Maintain Outperform Outperform
2018-11-28 UBS Maintain Buy Buy
2018-11-13 Citigroup Maintain Neutral Neutral
2018-11-08 RBC Capital Maintain Sector Perform Sector Perform
2018-11-05 Morgan Stanley Maintain Underweight Underweight
2018-11-02 Argus Research Upgrade Hold Buy
2018-11-02 Argus Upgrade Hold Buy
2018-11-01 Leerink Swann Maintain Outperform Outperform
2018-11-01 Raymond James Maintain Outperform Outperform
2018-11-01 Wells Fargo Maintain Outperform Outperform
2018-11-01 BMO Capital Maintain Outperform Outperform
2018-10-16 Barclays Maintain Underweight Underweight
2018-10-11 Morgan Stanley Maintain Underweight Underweight
2018-07-31 Citigroup Maintain Neutral Neutral
2018-07-27 Piper Sandler Maintain Overweight Overweight
2018-07-27 PiperJaffray Maintain Overweight Overweight
2018-07-27 JP Morgan Maintain Overweight Overweight
2018-05-22 B of A Securities Maintain Buy Buy
2018-05-22 Bank of America Maintain Buy Buy
2018-04-30 Stifel Nicolaus Maintain Hold Hold
2018-04-30 Stifel Maintain Hold Hold
2018-04-30 Citigroup Maintain Neutral Neutral
2018-02-06 Citigroup Maintain Neutral Neutral
2018-02-02 BMO Capital Maintain Outperform Outperform
2018-02-02 Barclays Maintain Overweight Overweight
2018-01-03 Evercore ISI Group Maintain Outperform Outperform
2018-01-03 Raymond James Upgrade Market Perform Outperform
2018-01-02 JP Morgan Upgrade Neutral Overweight
2018-01-02 B of A Securities Upgrade Neutral Buy
2018-01-02 Bank of America Upgrade Neutral Buy
2017-10-26 Barclays Maintain Overweight Overweight
2017-10-26 Morgan Stanley Maintain Equal Weight Equal Weight
2017-08-17 Citigroup Maintain Neutral Neutral
2017-07-27 Barclays Maintain Overweight Overweight
2017-07-25 Morgan Stanley Maintain Equal Weight Equal Weight
2017-07-11 BMO Capital Upgrade Market Perform Outperform
2017-06-30 Cantor Fitzgerald Maintain Overweight Overweight
2017-05-16 Goldman Sachs Maintain Buy Buy
2016-10-13 Wells Fargo Maintain Outperform Outperform
2016-09-15 Barclays Maintain Overweight Overweight
2016-07-28 UBS Maintain Neutral Neutral
2016-07-27 JP Morgan Maintain Neutral Neutral
2016-05-04 Evercore ISI Group Maintain Buy Buy
2016-04-25 Credit Suisse Maintain Neutral Neutral
2016-04-14 PiperJaffray Upgrade Neutral Overweight
2016-04-14 Piper Sandler Upgrade Neutral Overweight
2016-02-03 BMO Capital Maintain Market Perform Market Perform
2015-10-28 Leerink Swann Maintain Market Perform Market Perform
2015-08-11 Barclays Maintain Overweight Overweight
2015-07-30 Leerink Swann Downgrade Outperform Market Perform
2015-07-13 Deutsche Bank Maintain Hold Hold
2015-07-07 BMO Capital Downgrade Outperform Market Perform
2015-07-02 Barclays Maintain Overweight Overweight
2015-07-02 B of A Securities Downgrade Buy Neutral
2015-07-02 Bank of America Downgrade Buy Neutral
2015-06-30 Credit Suisse Downgrade Outperform Neutral
2015-06-24 Goldman Sachs Maintain Buy Buy
2015-05-19 Barclays Maintain Overweight Overweight
2015-04-24 BMO Capital Maintain Outperform Outperform
2015-04-20 JP Morgan Maintain Neutral Neutral
2015-02-18 JP Morgan Maintain Neutral Neutral
2014-10-17 Barclays Maintain Overweight Overweight
2014-10-17 Credit Suisse Maintain Outperform Outperform
2014-10-13 Morgan Stanley Maintain Equal Weight Equal Weight
2014-10-06 B of A Securities Maintain Buy Buy
2014-10-06 Bank of America Maintain Buy Buy
2014-09-17 JP Morgan Maintain Neutral Neutral
2014-07-18 JP Morgan Maintain Neutral Neutral
2014-07-15 Barclays Maintain Overweight Overweight
2014-03-17 Goldman Sachs Maintain Buy Buy
2014-01-27 Citigroup Maintain Neutral Neutral
2014-01-24 Deutsche Bank Maintain Hold Hold
2014-01-23 BMO Capital Maintain Outperform Outperform
2014-01-07 RBC Capital Downgrade Outperform Sector Perform
2013-11-18 Credit Suisse Upgrade Neutral Outperform
2013-10-23 Cowen & Co. Downgrade Outperform Market Perform
2013-10-18 Morgan Stanley Downgrade Overweight Equal Weight
2013-10-18 Raymond James Downgrade Outperform Market Perform
2013-10-02 Credit Suisse Downgrade Outperform Neutral
2013-09-04 CL King Upgrade Neutral Buy
2013-07-10 Credit Suisse Maintain Outperform Outperform
2013-05-16 Bank of America Maintain Buy Buy
2013-05-16 B of A Securities Maintain Buy Buy
2013-05-14 Morgan Stanley Maintain Overweight Overweight
2013-05-07 Barclays Upgrade Equal Weight Overweight
2013-04-15 Piper Sandler Maintain Overweight Overweight
2013-04-15 PiperJaffray Maintain Overweight Overweight
2013-04-12 Deutsche Bank Maintain Hold Hold
2013-03-25 Morgan Stanley Maintain Overweight Overweight
2013-01-04 Deutsche Bank Maintain Hold Hold
2012-12-20 Morgan Stanley Maintain Overweight Overweight
2012-11-27 Mizuho Downgrade Buy Neutral
2012-11-26 JP Morgan Maintain Overweight Overweight
2012-11-26 B of A Securities Maintain Buy Buy
2012-11-26 Bank of America Maintain Buy Buy
2012-11-20 Stifel Nicolaus Maintain Hold Hold
2012-11-15 Barclays Maintain Equal Weight Equal Weight
2012-10-11 Piper Sandler Maintain Overweight Overweight
2012-10-11 PiperJaffray Maintain Overweight Overweight
2012-10-10 Citigroup Maintain Neutral Neutral
2012-10-01 JP Morgan Maintain Overweight Overweight
2012-09-24 Deutsche Bank Downgrade Buy Hold
2012-09-19 BMO Capital Maintain Outperform Outperform
2012-07-25 Goldman Sachs Maintain Buy Buy
2012-07-20 Deutsche Bank Maintain Buy Buy
2012-07-09 Citigroup Maintain Neutral Neutral
2012-04-20 Citigroup Maintain Neutral Neutral
2012-04-20 UBS Maintain Buy Buy
2012-04-20 Deutsche Bank Maintain Buy Buy
2012-03-20 Morgan Stanley Maintain Overweight Overweight
2012-03-05 Dougherty Maintain Neutral Neutral
2012-03-05 Dougherty & Co. Maintain Neutral Neutral
2012-02-28 UBS Maintain Buy Buy
2012-02-24 Citigroup Upgrade Sell Neutral
2012-02-16 Standpoint Research Downgrade Buy Hold